Literature DB >> 4201654

Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia.

M Haghbin, D Armstrong, M L Murphy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4201654     DOI: 10.1002/1097-0142(197310)32:4<761::aid-cncr2820320405>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  17 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

3.  Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.

Authors:  M R Moody; R W Kessel; V M Young; P Fiset
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

4.  Immunoblot analysis of serological response to Pseudomonas aeruginosa septicaemia in man.

Authors:  R C Matthews; J P Burnie; S Tabaqchali
Journal:  J Clin Pathol       Date:  1986-12       Impact factor: 3.411

Review 5.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

6.  Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

7.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

8.  A facile approach for development of a vaccine made of bacterial double-layered membrane vesicles (DMVs).

Authors:  Sihan Wang; Jin Gao; Mo Li; Liguo Wang; Zhenjia Wang
Journal:  Biomaterials       Date:  2018-10-01       Impact factor: 12.479

9.  Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.

Authors:  J D Klinger; H A Cash; R E Wood; J J Miler
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

10.  Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.